Patents by Inventor Giusy Della Gatta

Giusy Della Gatta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
    Patent number: 11845989
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: December 19, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola, Gaurang Patel, Ying Hu, Carmelo Romano, Giusy Della Gatta, Trikaldarshi Persaud
  • Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors
    Publication number: 20220089664
    Abstract: The present disclosure provides methods of treating subjects having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, and methods of detecting Angiopoietin-Like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: July 27, 2021
    Publication date: March 24, 2022
    Inventors: Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola, Gaurang Patel, Ying Hu, Carmelo Romano, Giusy Della Gatta, Trikaldarshi Persaud
  • A RODENT MODEL OF B4GALT1-MEDIATED FUNCTIONS
    Publication number: 20210274759
    Abstract: This disclosure relates to genetically modified animals. More specifically, this disclosure relates to rodent animals in which an endogenous B4galt1 gene has been modified, e.g., to introduce a mutation that encodes an Asn to Ser substitution in the encoded B4galt1 protein at a position corresponding to position 352 in a human B4GALT1 protein, or to introduce a loss of function mutation (e.g., in a select tissue such as the liver). This disclosure also relates to use of such rodent animals in elucidating the role of B4galt1 in lipid metabolism.
    Type: Application
    Filed: March 3, 2021
    Publication date: September 9, 2021
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Giusy Della Gatta, Qing Fang, Alan Shuldiner
  • B4GALT1 Variants And Uses Thereof
    Publication number: 20200399617
    Abstract: Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.
    Type: Application
    Filed: July 2, 2020
    Publication date: December 24, 2020
    Inventors: May Montasser, Cristopher Van Hout, Alan Shuldiner, Giusy Della Gatta, Matthew Healy, Marja Puurunen
  • B4GALT1 cDNA variants and compositions comprising the same
    Patent number: 10738284
    Abstract: Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: August 11, 2020
    Assignees: Regeneron Pharmaceuticals, Inc., University of Maryland, Baltimore
    Inventors: May Montasser, Cristopher Van Hout, Alan Shuldiner, Giusy Della Gatta, Matthew Healy, Marja Puurunen
  • B4GALT1 Variants And Uses Thereof
    Publication number: 20180346888
    Abstract: Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein.
    Type: Application
    Filed: June 4, 2018
    Publication date: December 6, 2018
    Inventors: May Montasser, Cristopher Van Hout, Alan Shuldiner, Giusy Della Gatta, Matthew Healy, Marja Puurunen